Gateways to clinical trials

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 25, Issue 5, 2003, Pages 387-408

  Bayes M ^a   Rabasseda, X ^a   Prous, J R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANDOLAST; ANIDULAFUNGIN; APC 2059; ARGININE; ARIPIPRAZOLE; ARZOXIFENE; ASIMADOLINE; BEXAROTENE; CANNABIDIOL; CARIPORIDE; CCI 1004; CERIVASTATIN; CLEVUDINE; DALBAVANCIN; DELIGOPARIN; DROTRECOGIN; E 5564; ECULIZUMAB; EMTRICITABINE; ENFUVIRTIDE; EPIGALLOCATECHIN; EPLERENONE; ESOMEPRAZOLE; N1,N11 DIETHYLNORSPERMINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BREAST DISEASE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; EYE DISEASE; GASTROINTESTINAL DISEASE; GENITAL SYSTEM DISEASE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; INFESTATION; KIDNEY DISEASE; LYMPHATIC SYSTEM DISEASE; MEDICAL LITERATURE; REVIEW; SKIN DISEASE; URINARY TRACT DISEASE;

CLINICAL PROTOCOLS; CLINICAL TRIALS; DRUG THERAPY; HUMANS;

EID: 0038494685     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (134)

1. Macdougall, I.C., Matcham, J., Gray, S.J. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. Nephrol Dial Transplant 2003, 18(3): 576.
2. Branson, K., Ewing, J., So, J. et al. The place of voriconazole in the practical management of neutropaenia/BMT patients. Br J Haematol 2003, 121 (Suppl. 1): Abst 118.
3. Weber, W., Harnisch, L., Jessel, A. Lessons learned from a phase III population pharmacokinetic study of cariporide in coronary artery bypass graft surgery. Clin Pharmacol Ther 2002, 71(6): 457.
4. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: The ENCORE 1 Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation 2003, 107(3): 422.
5. Seiffert, D., Stern, A.M., Ebling, W. et al. Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: Implications for the etiology of thrombocytopenia. Blood 2003, 101(1): 58.
6. Pitt, B. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarc- tion. New Engl J Med 2003, 348(14): 1309.
7. Antman, E., Cooper, H., Domanski, M. et al. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: A randomised controlled trial. Lancet 2002, 360(9341): 1189.
8. Welsh, R.C., Travers, A., Sosnowski, T. et al. Prehospital fibrinolysis: Is it safe, feasible, and efficient in a large urban North American center? J Am Coll Cardiol 2002, 39 (5, Suppl. A): 279A.
9. Fu, Y., Wagner, G., Goodman, S., Van de Werf, F., Granger, C.B., Armstrong, P.W. Combination tenecteplase and abciximab results in more complete ST resolution: Findings from the ASSENT 3 ECG substudy. J Am Coll Cardiol 2002, 39 (5, Suppl. A): 306A.
10. McCullough, P.A., Nowak, R.M., McCord, J. et al. B-Type natri-uretic peptide adds to clinical judgement in the diagnosis of heart failure: A Bayesian analysis from the BNP Multinational Study. J Am Coll Cardiol 2002, 39 (5, Suppl. A): 140A.
11. Flack, J.M., Oparil, S., Pratt, J.H. et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003, 41(7): 1148.
12. Turpie, A.G., Bauer, K.A., Eriksson, B.I., Lassen, M.R., Smith, D.A. Fondaparinux is superior to enoxaparin for venous thromboembolism prevention in major orthopedic surgery irrespective of patient characteristics. J Am Geriatr Soc 2003, 51 (4, Suppl.): Abst A31.
13. Reiter, M. et al. Idraparinux and liver enzymes: Observations from the PERSIST trial. Blood Coagul Fibrinolysis 2003, 14(1): 61.
14. Leon, M., Mohler, E. Results of a dose-ranging diagnostic trial of magnetic resonance angiography with MS-325, a blood pool contrast agent, for the detection of vascular occlusive disease in the aortoiliac region. J Am Coll Cardiol 2002, 39 (5, Suppl. A): 368A.
15. Rajagopalan, S., Trachtenberg, J., Mohler, E. et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI- 1023) to patients with claudication. Am J Cardiol 2002, 90(5): 512.
16. Campochiaro, P. Phase 2 study results of oral results PKC412 in diabetic macular edema. Annu Meet Assoc Res Vision Ophthalmol (May 4, 2003, Fort Lauderdale) 2003: Abst 4286.
17. Halpern, M.T., Covert, D.W., Robin, A.L. Projected impact of travoprost versus both timolol and latanoprast on visual field deficit progression and costs among black glaucoma subjects. Trans Am Ophthalmol Soc 2002, 100: 109.
18. Noecker, R.S., Dirks, M.S., Choplin, N.T., Bernstein, P., Batoosingh, A.L., Whitcup, S.M. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003, 135(1): 55.
19. Fellman, R.L., Sullivan, E.K., Ratliff, M. et al. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: A 6-month, masked, multicenter trial. Ophthalmology 2002, 109(5): 998.
20. Rosenfeld, P.J., Villate, N., Feuer, W.J., Puliafito, C.A., McCluskey, E.R. RhuFab V2 (anti-VEGF antibody fragment) in neovascular AMD: Safety, tolerability and efficacy of multiple, escalating dose intravitreal injections. Annu Meet Assoc Res Vision Ophthalmol (May 4, 2003, Fort Lauderdale) 2003: Abst 970.
21. Heier, J.S., Sy, J.R., McCluskey, E.R. RhuFab V2 in wet AMD - 6 month continued improvement following multiple intravitreal injections. Annu Meet Assoc Res Vision Ophthalmol (May 4, 2003, Fort Lauderdale) 2003: Abst 972.
22. Tornambe, P.E., Fox, G.M., Poliner, L.S. et al. A double-masked, randomized, placebo-controlled, dose-escalating study of a single intravitreal injection of INS37217 in subjects with retinal detachment. Annu Meet Assoc Res Vision Ophthalmol (May 4, 2003, Fort Lauderdale) 2003: Abst 2027.
23. Tremaine, W.J. et al. Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): An open-label pilot study. Aliment Pharmacol Ther 2002, 16(3): 407.
24. Korzenik, J., Miner, P. Jr., Stanton, D. et al. Multicenter, randomized, double-blind, placebo-controlled trial of deligoparin (ultra low molecular weight heparin) for active ulcerative colitis. Dig Dis Week (May 17, 2003, Orlando) 2003: Abst 539.
25. Johansen, J.F., Tougas, G., Chey, W.D. et al. Tegaserod provides rapid and sustained relief of constipation, abdominal bloating/dis- tension, and abdominal discomfort/pain in patients with chronic constipation. Dig Dis Week (May 17, 2003, Orlando) 2003: Abst 371.
26. Shah, H.A., Jafri, W., Butt, J.A., Mohsin, A., Khan, I. An open label study to determine the efficacy and tolerability of tegaserod in the treatment of constipation dominant irritable bowel syndrome (IBS-C). Dig Dis Week (May 17, 2003, Orlando) 2003: Abst T1435.
27. Lin, S., Zhou, L., Liu, X. et al. Tegaserod provides rapid, effective relief of abdominal pain/discomfort, bloating and constipation in Chinese patients with irritable bowel syndrome with constipation (IBS-C). Dig Dis Week (May 17, 2003, Orlando) 2003: Abst S1017.
28. Kellow, J. et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003, 52(5): 671.
29. Nyhlin, H., Bang, C., Elsborg, L. et al. Tegaserod is an effective and safe therapy for irritable bowel syndrome in a Nordic popu- lation. Dig Dis Week (May 17, 2003, Orlando) 2003: Abst M1645.
30. Sandborn, W.J., Feagan, B., Radford-Smith, G., Kovacs, A., Enns, R., Patel, J. A randomized, placebo-controlled trial of CDP571, a humanized monoclonal antibody to TNF-α, in patients with mod- erate to severe Crohn's disease. Dig Dis Week (May 17, 2003, Orlando) 2003: Abst 469.
31. Hanauer, S., Present, D., Targan, S.R., Kam, L., Patel, J., Sandborn, W.J. CDP571, a humanized monoclonal antibody to TNF-α, a well tolerated alternative in Crohn's disease patients who have experienced hypersensitivity reactions to infliximab. Dig Dis Week (May 17, 2003, Orlando) 2003: Abst T1357.
32. Rutgeerts, P., Donoghue, S., Palmer, T. Quality of life improvements in a phase 2 study of natalizumab for active Crohn's disease. Dig Dis Week (May 17 2003, Orlando) 2003: Abst M1585.
33. Vieth, M. et al. The effects of esomeprazole on the squamous epithelium of the esophagus: An analysis based on the ProGERD study initiative. Dig Dis Week (May 19, 2002, San Francisco) 2002: Abst S1298.
34. Wilder-Smith, C.H. et al. Esomeprazole 40 mg provides faster and more effective acid control than rabeprazole 20 mg in patients with symptoms of GERD. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.A.065.
35. Dohmen, W. et al. Onset and duration of pain relief in gastro- esophageal reflux disease (GERD). A clinical comparison of lan- soprazole, omeprazole MUPS and esomeprazole. Dig Dis Week (May 19, 2002, San Francisco) 2002: Abst S1296.
36. Helbling, B. et al. Pegylated (40 kDa, branched) interferon alfa-2a (PEG-IFN) and ribavirin (RIBA) in IFN-naive patients with hepatitis C and advanced fibrosis/cirrhosis: Interim results of a randomized, controlled trial. Dig Dis Week (May 19, 2002, San Francisco) 2002: Abst 84.
37. Marcellin, P., Sacks, S., Lau, G.K. et al. A dose escalating trial evaluating the safety and antiviral activity of clevudine in patients with chronic HBV infection. Dig Dis Week (May 17, 2003, Orlando) 2003: Abst 337.
38. Ferenci, P. et al. Prediction of early virologic response to treatment with 40KD pegylated (PEG)-interferon (IFN) alfa2a/ribavirin in patients with chronic hepatitis C (genotype 1). Dig Dis Week (May 19, 2002, San Francisco) 2002: Abst 81.
39. Barth, H. et al. Analysis of the effect of IL-12 therapy on immunoregulatory T-cell subsets in patients with chronic hepatitis C infection. Hepato-Gastroenterology 2003, 50(49): 201.
40. Wade, D.T., Robson, P., House, H., Makela, P., Aram, J. A preliminaly controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003, 17(1): 21.
41. Popescu, A., Edwards, A., Acquadro, M., Hord, E. Opioid rotation to methadone in neutropathic pain syndromes. 22nd Annu Sci Meet Am Pain Soc (March 20, 2003, Chicago) 2003: Abst 912.
42. Millett, T. Botulinum toxin type B (Myobloc®) in the treatment of refractory cervicothoracic myofascial pain syndrome. 22nd Annu Sci Meet Am Pain Soc (March 20, 2003, Chicago) 2003: Abst 704.
43. Day, M., Heavner, J., Raj, P., Racz, G., Shah, R. Myobloc® for the treatment of myofascial low back pain of the psoas and quadratus lumborum muscles. 22nd Annu Sci Meet Am Pain Soc (March 20, 2003, Chicago) 2003: Abst 708.
44. Neiman, R. Botulinum toxin type B (Myobloc®) in the treatment of refractory myofascial pain conditions. 22nd Annu Sci Meet Am Pain Soc (March 20, 2003, Chicago) 2003: Abst 701.
45. Reynolds, L.W. et al. The COX-2 specific inhibitor, valdecoxib, is an effective, opioid-sparing analgesic in patients undergoing total knee arthroplasty. J Pain Symptom Manage 2003, 25(2): 133.
46. Heavner, J., Day, M., Shah, R., Raj, P., Racz, G. Demographics and doses of Myobloc® (botulinum toxin type B) used to treat pain and spasticity from patient registry. 22nd Annu Sci Meet Am Pain Soc (March 20, 2003, Chicago) 2003: Abst 909.
47. Lalezari, J.P., Eron, J.J., Carlson, M. et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003, 17(5): 691.
48. Wasilewski, M., Disch, D., McGill, J. et al. Equivalence of shorter course therapy with oritavancin compared to vancomycin/cephalexin in complicated skin/skin structure infections (CSSI). 12th Eur Congr Clin Microbiol Infect Dis (April 24, 2002, Milan) 2002: Abst O135.
49. Krause, D., Goldstein, B., Wible, M., Kilfoil, G., Henkel, T. A phase 2 dose-ranging study of the safety, and efficacy of anidula- fungin in invasive candidiasis. Clin Microbiol Infect 2003, 9 (Suppl. 1): Abst 0403.
50. Saag, M., Cahn, P., Raffi, R. et al. A randomized, double-blind, multicenter comparison of emtricitabine QD to stavudine BID. 42nd Intersci Conf Antimicrob Agents Chemother (Sept 27, 2002, San Diego) 2002: Abst LB-1.
51. Rodriguez-French, A., Nadler, J.P. The NEAT study: GW433908 efficacy and safety in anti-retroviral therapy (ART) naive subjects, preliminary 24-week results. 42nd Intersci Conf Antimicrob Agents Chemother (Sept 27, 2002, San Diego) 2002: Abst H-166.
52. Seltzer, E., Goldstein, B., Dorr, M.B., Dowell, J., Perry, M., Henkel, T. Dalbavancin: Phase 2 demonstration of efficacy of a novel, weekly dosing regimen in skin and soft tissue infections. Clin Microbiol Infect 2003, 9 (Suppl. 1): Abst O143.
53. Fogarty, C. et al. Telithromycin is an effective treatment in high-risk patients with community-acquired pneumonia. J Am Geriatr Soc 2002, 50 (4, Suppl.): Abst P290.
54. Hale, B.R., Owusu-Agyei, S., Fryauff, D.J. et al. A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin Infect Dis 2003, 36(5): 541.
55. Vincent, J.L., Angus, D.C., Artigas, A. et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003, 31(3): 834.
56. Kolobov, A., Simbirtsev, A., Bokovanov, V., Vasil'eva G., Tuthill, C., Rudolph, A. Pilot clinical trial of γ-Glu-Trp in lung tuberculosis. 42nd Intersci Conf Antimicrob Agents Chemother (Sept 27, 2002, San Diego) 2002: Abst L-676.
57. D'Haese, P.C., Spasovski, G.B., Sikole, A. et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol™) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003, 63 (Suppl. 85): S73.
58. Davidson, M., McGarry, T., Bettis, R. et al. Ezetimibe co-administered with simvastatin in 668 patients with primary hypercholes- terolemia. J Am Coll Cardiol 2002, 39 (5, Suppl. A): 226A.
59. Knopp, R.H., Gitter, H., Truitt, T. et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003, 24(8): 729.
60. Melani, L., Mills, R., Hassman, D. et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Eur Heart J 2003, 24(8): 717.
61. Ballantyne, C.M. et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. A prospective, randomized, double-blind trial. Circulation 2003, 107(19): 2409.
62. Recker, D.P., Kent, J.D., Hounslow, N., Lau, W. Valdecoxib, a novel COX-2 specific inhibitor, is safe and well tolerated in elderly osteoarthritis (OA) and rheumatoid arthritis (RA) patients. J Am Geriatr Soc 2002, 50 (4, Suppl.): Abst P410.
63. Fleischmann, R., Tesser, J., Sun, G. Safety of anakinra (interleukin-1 receptor antagonist) in patients receiving standard treatments for rheumatoid arthritis: A large phase III study. 66th Annu Meet Am Coll Rheumatol (Oct 25, 2002, New Orleans) 2002: Abst 1541.
64. Emery, P., Williams, G.R., Li, T., Breazna, A., Becker, J.C. Improvement in health-related quality of life in patients with active rheumatoid arthritis: CTLA41g combined with etanercept compared to etanercept plus placebo. 66th Annu Meet Am Coll Rheumatol (Oct 25, 2002, New Orleans) 2002: Abst 1376.
65. Rau, R. et al. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): A double blind, placebo controlled dose-finding study in rheuma- toid arthritis. J Rheumatol 2003, 30(4): 680.
66. Whelton, A., Kent, J.D., Recker, D.P. No difference in thrombotic events in rheumatoid arthritis patients: Valdecoxib vs. naproxen and placebo. 66th Annu Meet Am Coll Rheumatol (Oct 25, 2002, New Orleans) 2002: Abst 1370.
67. Melian, A., van der Heijde, D.M., James, M.K. et al. Etoricoxib in the treatment of ankylosing spondylitis (AS). 66th Annu Meet Am Coll Rheumatol (Oct 25, 2002, New Orleans) 2002: Abst 1131.
68. Nicolson, M. et al. A phase I clinical and pharmacokinetic study of oral Ro 31-7453, a novel cell cycle inhibitor, administered in combination with gemcitabine. Proc Am Assoc Cancer Res 2002, 43: Abst 1369.
69. Crombet, T., Torres, L., Neninger, E. et al. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial- derived cancer. J Immunother 2003, 26(2): 139.
70. Fabian, C.J. et al. Effects of arzoxifene, a third generation SERM, on serum osteocalcin levels and bone mineral density in pre- and post-menopausal women at increased risk for breast cancer. Proc Am Assoc Cancer Res 2002, 43: Abst 4081.
71. Pitot, H.C., Reid, J.M., Sloan, J.A. et al. A phase I study of bize-lesin (NSC 615291) in patients with advanced solid tumors. Clin Cancer Res 2002, 8(3): 712.
72. Jones, S. et al. Greater duration of response with faslodex (fulves-trant; ICI 182,780) compared to arimidex (anastrozole). Proc Am Assoc Cancer Res 2002, 43: Abst 3721.
73. Petry, K.U., Garcia, F., Gold, M.A. et al. A randomized placebo-controlled study of ZYC101a for the treatment of high grade intraepithelial neoplasia. 5th Int Congr Eur Res Organ Genit Infect Neoplasia (EUROGIN) (April 13, 2003, Paris) 2003: Abst SS15-09.
74. Kortmansky, J. et al. Response to the combination of bryostatin-1 and paclitaxel is dose-dependent. Proc Am Assoc Cancer Res 2002, 43: Abst 2737.
75. Hussain, M.M. et al. A phase II trial of carboxyamido-triazole (CA1) in patients with refractory epithelial ovarian cancer. Proc Am Assoc Cancer Res 2002, 43: Abst 3716.
76. Hahm, H.A. et al. Phase I study of N-1,N-11-diethylnorspermine in patients with non-small cell lung cancer. Clin Cancer Res 2002, 8(3): 684.
77. Horti, J. et al. Preliminary results of a phase I trial of TZT-1027, an inhibitor of tubulin polymerization, in patients with advanced non-small cell lung cancer. Proc Am Assoc Cancer Res 2002, 43: Abst 2744.
78. Adjei, A.A., Mauer, A., Marks, R. et al. A phase II study of the farnesyltransferase inhibitor R115777 in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 1156.
79. Nicol, A.J., Tazbirkova, A., Okai, M. et al. Immune therapy with KRN7000-pulsed dendritic cells modulates peripheral blood V α24+Vβ11+NKT cells and NK cells: Results of a phase I study. Blood 2002, 100 (11, Part 1): Abst 2658.
80. Cohen, S.J., Ho, L., Ranganathan, S. et al. Phase II and pharmacodynamic trial of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 545.
81. Gordon, A.N., Stringer, A., Edwards, R.P., Whiteside, T.L., Fingert, H.J., Schultes, B.C. Clinical and immunologic outcome of patients (pts) with recurrent epithelial ovarian cancer (EOC) treated with OvaRex® MAb (Ov) and chemotherapy (Ct). 33rd Annu Meet Soc Gynecol Oncol (March 16, 2002, Miami Beach) 2002: Abst 78.
82. Macdonald, J.S., Chansky, K., Whitehead, R., Wade, J., Giguere, J., Abbruzzese, J.L. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest Oncology Group (SWOG) study. Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 548.
83. Bedikian, A.Y. et al. Phase II trial of 9-nitro camptothecin (RFS-2000) for patients with metastatic choroidal and non-choroidal melanoma. Proc Am Assoc Cancer Res 2002, 43: Abst 2746.
84. Stone, R., Yu, D., Stock, W. et al. A phase II trial of homoharringtonine (HHT) in combination with low-dose cytarabine (lodac) via continuous intravenous infusion (CIVI) for newly diagnosed patients (pts) with chronic myeloid leukemia (CML): CALGB 19804. Blood 2002, 100 (11, Part 1): Abst 3101.
85. Lessin, S.R., Steckel, S.D., Wu, H. A phase II trial to evaluate the efficacy of topical 1% bexarotene (Targretin®) gel in patients with parapsoriasis (T(O) cutaneous T cell lymphoma). 64th Annu Meet Soc Invest Dermatol (April 30, 2003, Miami Beach) 2003: Abst 1199.
86. Czuczman, M., Witzig, T.E., Gaston, I. et al. Zevalin radioimmunotherapy is not associated with an increased incidence of secondary myelodysplastic syndrome (MDS) or acnte myelogenous leukemia (AML). Blood 2002, 100 (11, Part 1): Abst 1386.
87. Benson, A.L.B. III. et al. ZD9331 plus topotecan in patients with refractory solid malignancies. Proc Am Assoc Cancer Res 2002, 43: Abst 2757.
88. Briasoulis, E.A. et al. Phase II study on glufosfamide administered as a 60 minute infusion every 3 weeks in advanced pancreatic cancer. Proc Am Assoc Cancer Res 2002, 43: Abst 3713.
89. Suh-Burgmann, E., Sivret, J., Duska, L.R., Del Carmen, M., Seiden, M.V. Long-term administration of intravaginal dehydroepiandrosterone on regression of low-grade cervical dysplasia A pilot study. Gynecol Obstet Invest 2003, 55(1): 25.
90. Raymond, E. et al. Phase II and pharmacokinetic multicentre study of RFS 2000 (9-nitro-camptothecin) administered orally as a 5-day-on 2-day-off schedule in patients with glioblastoma mul- tiforme. Proc Am Assoc Cancer Res 2002, 43: Abst 3709.
91. Pitako, J.A., Haas, P., van den Bosch, J., Mueller-Berndorf, H., Wijermans, P.W., Lubbert, M. Low-dose decitabine (DAC) in elderly MDS patients: Quantification of hospitalization vs outpa- tient management and survival. Blood 2002, 100 (11, Part 1): Abst 3134.
92. Ho, A.Y.L., Lim, S., Westwood, N. et al. Imatinib mesylate in myelofibrosis: Sustained improvements in platelet counts and splenomegaly. Br J Haematol 2003, 121 (Suppl. 1): Abst 212.
93. Apperley, J.F., Dimitrijevic, S., Browne, P. et al. Imatinib (STI571, Glivec) for chronic Ph-negative myeloproliferative disorders associated with eosinophilia. Br J Haematol 2003, 121 (Suppl. 1): Abst 213.
94. Jeste, D.V., De Deyn, P., Carson, W. et al. Aripiprazole in dementia of the Alzheimer's type. J Am Geriatr Soc 2003, 51 (4, Suppl.): Abst P543.
95. Boon, P. et al, Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy. Epilepsy Res 2002, 48(1-2): 77.
96. Gwynn, M., Baker, T., English, J. Double-blind, placebo-controlled study of Myobloc® (botulinum toxin B) for the treatment of chronic headache. 22nd Annu Sci Meet Am Pain Soc (March 20, 2003, Chicago) 2003: Abst 652.
97. Pozo-Rosich, P., Siow, C, Silberstein, S.D. Frovatriptan and cluster headache. Neurology 2003, 60 (5, Suppl. 1): Abst P03.158,
98. Krusz, J. Intradermal botulinum toxin type B for headaches of cervical origin. 22nd Annu Sci Meet Am Pain Soc (March 20, 2003, Chicago) 2003: Abst 958.
99. Lake, A. III, Saper, J. Botolinum toxin type B for migraine prophylaxis: A 4-month open-label prospective outcome study. 22nd Annu Sci Meet Am Pain Soc (March 20, 2003, Chicago) 2003: Abst 696.
100. Silberstein, S.D., Elkind, A.H., Schreiber, C. Frovatriptan, a selective 5HT1B/1D agonist, is effective for prophylaxis of menstrually associated migraine. Abst S15.004.
101. 1B/1D agonist, used for prophylaxis of menstrually associated migraine. Neurology 2003, 60 (5, Suppl. 1): Abst P06.141.
102. Pande, A.C., Crockatt, J.G., Feltner, D.E. et al. Pregabalin in generalized anxiety disorder: A placebo-controlled trial. Am J Psychiatry 2003, 160(3): 533.
103. Keck, P.E. Jr., Versiani, M., Potkin, S., West, S.A., Giller, E., Ice, K. Ziprasidone in the treatment of acute bipolar mania: A three- week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003, 160(4): 741.
104. Chapple, C.R., Arano, P., Bosch, J.H.R., De Ridder, D., Kramer, A., Ridder, A.M. YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase-II, dose-finding study. 32nd Annu Meet Int Continence Soc (Aug 28, 2002, Heidelberg) 2002: Abst 75.
105. Smith, N., Grimes, I., Ridge, S., Tempel, D., Uchida, T. YM905 is effective and safe as treatment of overactive bladder in women and men: Results from phase II study. 32nd Annu Meet Int Continence Soc (Aug 28, 2002, Heidelberg) 2002: Abst 222.
106. Bramer, S.L., Zhu, Z., Brisson, J., Bricmon, P. Pharmacokinetics (PK) and pharmacodynamics (PD) of OPC-51803 in adult patients with urinary incontinence. Clin Pharmacol Ther 2002, 71(2): Abst MPI-97.
107. Hillmen, P., Hall, C., Marsh, J. et al. Eculizumab, a C5 complement blocking antibody, is the first therapy to reduce transfusion requirements in patients with paroxysmal nocturnal haemoglobinuria (PNH). Br J Haematol 2003, 121 (Suppl. 1): Abst 257.
108. Lebret, T., Herve, J.-M., Gorny, P., Worcel, M., Botto, H. Efficacy and safety of a novel combination of L-arginine glutamate and yohimbine hydrochloride: A new oral therapy for erectile dysfunction. Eur Urol 2002, 41(6): 608.
109. Hatzchristou, D., Montorsi, F., Porst, H., Taylor, T., Bandel, T. Efficacy of vardenafil in a flexible dose regimen: A placebo-controlled trial. J Am Geriatr Soc 2003, 51 (4, Suppl.): Abst P171.
110. Donatucci C., Gittelman, M., Homering, M., Thibonnier, M. Vardenafil improved satisfaction with erection hardness, orgasmic function, and sexual experience in men with erectile dysfunction irrespective of age. J Am Geriatr Soc 2003, 51 (4, Suppl.): Abst P167.
111. Salvi, S.S., Caserini, M., D'Amato, M., Rovati, L., Holgate, S.T., Arshad, H. Andolast reduces airway hyperresponsiveness (AHR) to adenosine-5′-monophosphate (AMP) dose-dependently in mild atopic asthmatic subjects. 98th Int Conf Am Thorac Soc (May 17, 2002, Atlanta) 2002: Abst A38.
112. Menzies-Gow, A., Flood-Page, P., Compton, C. et al. A double blind, placebo-controlled, parallel group study to assess the effect of mepolizumab (humanised monoclonal anti-IL-5 antibody) on bone marrow and peripheral blood eosinophils and eosinophil progenitors in atopic asthmatics. 98th Int Conf Am Thorac Soc (May 17, 2002, Atlanta) 2002: Abst H47.
113. Seeger, W., Spragg, R.G., Taut, J.H., Häfner, D., Lewis, J.F. Treatment with rSP-C surfactant reduces mortality in ARDS due to primary pulmonary events. 98th Int Conf Am Thorac Soc (May 17 2002, Atlanta) 2002: Abst 409.
114. Friedrich, M., Wolff, G., Philipp, S. et al. Bimosiamose, a panselectin antagonist improves disease manifestation both in human psoriatic skin SCID mice and psoriatic patients - selectin antago- nists as a new treatment strategy for inflammatory diseases. 64th Annu Meet Soc Invest Dermatol (April 30, 2003, Miami Beach) 2003: Abst 0367.
115. Heffernan, M., Matheson, R.T., Gottlieb, A.B., Chieffo, N., Spellman, M.C., Totoritis, M.C. Results of two phase II multiple-dose trials of an anti-CD80 monoclonal antibody (IDEC-114) in patients with psoriasis. 64th Annu Meet Soc Invest Dermatol (April 30, 2003, Miami Beach) 2003: Abst 0400.
116. Dulude, H., Marbury, T., Odland, M. et al. Escalating single doses of CJC-1004, a locally acting antithrombotic agent in hemodialysis patients with vascular access occlusion. J Am Coll Cardiol 2002, 39 (9, Suppl. B): 227B.
117. Uesugi, T. et al. The efficacy of lafutidine in improving preoperative gastric fluid property: A comparison, with ranitidine and rabeprazole. Anesth Analg 2002, 95(1): 144.
118. Delgado-Aros, S., Chial, H.J., Camilleri, M. et al. Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol - Gastrointest Liver Physiol 2003, 284(4): G558.
119. Stratton, S.P. et al. Phase IIa study of safety, tolerance, and sun protection factor of topical EGCG ointment in subjects with Fitzpatrick type II-III skin. Proc Am Assoc Cancer Res 2002, 43: Abst 5663.
120. Sachse, R., Cawello, W., Auer, S., Horstmann, R. Pharmacodynamics of multiple dose treatment with the novel antimuscarinic drug fesoterodine. Naunyn-Schmied Arch Pharmacol 2002, 365 (Suppl. 1): Abst 413.
121. Sachse, R., Cawello, W., Haag, C., Horstmann, R. Pharmacodynamics and pharmacokinetics of ascending multiple oral doses of the novel bladder-selective antimuscarinic fesoterodine. Eur Urol Suppl 2003, 2(1): Abst 111.
122. Peltonen, J.M., Huupponen, R., Ahokoski, O., Merivuori, H., Savola, J.-M., Juujarvi, P. Tolerability and safety of buccal JP-1730. A phase I study in healthy male volunteers. Mov Disord 2002, 17 (Suppl. 5): Abst P292.
123. Shimizu, K. Combined effects of vasopressin V2 receptor antagonist and loop diuretic in humans. Clin Nephrol 2003, 59 (3): 164.
124. Weikel, J.C., Wichniak, A., Ising, M. et al. Ghrelin promotes slow-wave sleep in humans. Am J Physiol - Endocrinol Metab 2003, 284(2): E407.
125. Moraga, F. Immunogenicity and reactogenicity for the co-admin- istration of a hexavalent vaccine with a conjugated meningitis C vaccine. 21st Annu Meet Eur Soc Paediatr Infect Dis (April 9, 2003, Taormina) 2003: Abst 6011.
126. Itoh, H., Naito, M., Takeyama, M. Effects of lafutidine on human plasma levels of somatostatin, calcitonin gene-related peptide, gastrin, secretin, and motilin. Clin Pharmacol Ther 2002, 71(2): Abst TPII-23.
127. Kashiwagi, K., Tsukahara, S. Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost. Br J Ophthalmol 2003, 87 (3): 297.
128. Sharkey, K.M., Eastman, C.I. Melatonin phase shifts human circadian rhythms in a placebo-controlled simulated night-work study. Am J Physiol - Regul Integr Comp Physiol 2002, 282 (2): R454.
129. Pawlikowski, M., Kolomecka, M., Wojtczak, A., Karasek, M. Effects of six months melatonin treatment on sleep quality and serum concentrations of estradiol, cortisol, dehydroepiandrosterone sulfate, and somatomedin C in elderly women. Neuroendocrinol Lett 2002, 23 (Suppl. 1): 17.
130. Hayden, F., Liu, S., Villano, S., McKinlay, M. Efficacy and tolerability of long-term pleconaril chemoprophylaxis for picornavirus illness in adults. Clin Microbiol Infect 2003, 9 (Suppl. 1): Abst O145.
131. Baisley, K. et al. Rabeprazole 20 mg compared with esomeprazole 40 mg in the control of intragastric pH in healthy volunteers. J Gastroenterol Hepatol 2002, 17 (Suppl.): Abst P.C.095d.
132. Saruwatari, J., Shindo, J., Hisaeda, S., Nakagawa, K., Ishizaki, T. The in vivo effect of a herbal medicine, sho-saiko-to, on cytochrome P450 1A2 and xanthine oxidase activities. Clin Pharmacol Ther 2002, 71(2): Abst TPII-84.
133. Sarich, T.C., Woltz, M., Eriksson, U.G. et al. Effects of ximelagatran, an oral direct thrombin inhibitor, hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. J Am Coll Cardiol 2003, 41(4): 557.
134. Lynn, M., Rossignol, D.P., Wheeler, J.L. et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis 2003, 187(4): 631.